Regulatory Support — Drugs/Biologics

Studies using an investigational drug (not FDA-approved) in a clinical study are regulated by the Food and Drug Administration (FDA). Additionally, some studies testing FDA-approved drugs when used in and investigational way (“off-label”, new patient population, new dosage, new route of administration, etc.) are also regulated by the FDA. Specific requirements regarding the development, manufacturing, documentation, as well as other specific requirements may be needed to comply with the FDA regulations and law. Therefore, we offer support to Georgia Tech faculty, students, and staff in complying with all applicable regulations and laws. Please see the FAQs below for more detail.

What is considered to be a drug?

What is considered to be a biologic?

When should I get Regulatory Affairs involved?

Does my study need an IND?

Who submits an IND to the FDA?

How does Regulatory Affairs support the manufacturing process?

How does Regulatory Affairs support the IRB process?

When do I report adverse events to the FDA?

Does Regulatory Affairs help with FDA meeting submissions?

Does Regulatory Affairs help with marketing applications?